Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Seeking Alpha
Follow Q2: 2024-08-07 Earnings Summary Play Call Press Release 10-Q EPS of -$0.59 beats by $0.24 | Revenue of beats by $0.00 Relmada Therapeutics, Inc. ( NASDAQ: RLMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Rudy Li - Leerink Partners Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Operator Good afternoon. Welcome to the Relmada Therapeutics Inc.'s Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode. [Operator Instructions] This call is being recorded on Wednesday, August 7, 2024. I would now like to turn the conference over to Tim McCarthy, LifeSci Advisors. Please go ahead, sir. Tim McCarthy Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Dr. Sergi
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.MarketBeat
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmPR Newswire
- Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]Yahoo! Finance
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmGlobeNewswire
- Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 8/7/24 - Beat
RLMD
Sec Filings
- 9/13/24 - Form EFFECT
- 9/11/24 - Form 4
- 9/11/24 - Form 4
- RLMD's page on the SEC website